甘草酸表面修饰万乃洛韦白蛋白纳米粒的制备及其肝靶向性研究

以万乃洛韦为模型药物 ,去溶剂化法制备普通载药纳米粒 ,结合高碘酸盐氧化法制备甘草酸 -万乃洛韦白蛋白纳米粒偶联物。对其表面甘草酸密度、形态、大小及其分布、体外释药特性、载药量、包封率、动物体内肝分布和体外肝细胞的摄取情况进行了研究。修饰纳米粒表面甘草酸密度为 9;平均粒径 d0 .5=2 6 8± 2 3nm;载药量1.35 % ;包封率 6 8.76 % ;体外释药符合双相动力学规律 ;对肝细胞具有选择靶向性。静注 15 min后 ,有 6 9.89%集中在肝脏 ,对照组为 6 4 .82 % ,二者之间存在显著差异 (P<0 .10 )。甘草酸表面修饰白蛋白纳米粒制备成功 ,为肝细胞靶向给药提供了新途径。

Preparation of Valaciclovir Loaded Bovine Serum Albumin Nanoparticles Surface-modified with Glycyrrhizin and Its Characteristics of Targeting to Liver

The valaciclovir was used as the model drug, the bovine serum albumin nanoparticles (BSA-NP) were prepared by desolvation process. Glycyrrhizin (GL) was oxidized by sodium periodate to be conjugated to surface reactive amino groups (SRAG) of the VACV-BSA-NP. Gel filtration method combined with HPLC method verified that GL was covalent coupling to the surface of VACV-BSA-NP with mean 9 GL residues per albumin molecule. The mean diameter of the VACV-BSA-NP-GL was 268 +/- 23 nm, the drug loading was 1.35%, and embedding ratio was 68.76%. The characteristics of release in vitro were in accord with two-phase kinetics. The uptake amount of VACV-BSA-NP-GL by primary cultured rat hepatocytes in vitro was higher, compared to the control-VACV-BSA-NP. 69.89% and 64.82% of the VACV were concentrated in liver at 15 min after i.v. VACV-BSA-NP-GL and VACV-BSA-NP, respectively. There is a significant difference between surface-modified group and control group (P<0.10). VACV-BSA-NP-GL was successfully prepared, which is considered to be a novel drug delivery system for targeting to hepatocytes.